EMFAT
NBIX icon

Emerald Mutual Fund Advisers Trust’s Neurocrine Biosciences NBIX Stock Holding History

Emerald Mutual Fund Advisers Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-82,212
Closed -$3.78M – 273
2017
Q2 		$3.78M Sell
82,212
-140,400
-63% -$6.81M 0.16% 152
2017
Q1 		$9.64M Hold
222,612
– – 0.44% 78
2016
Q4 		$8.62M Sell
222,612
-62,178
-22% -$2.81M 0.41% 88
2016
Q3 		$14.4M Buy
284,790
+19,399
+7% +$966K 0.73% 50
2016
Q2 		$12.1M Sell
265,391
-31,392
-11% -$1.45M 0.68% 53
2016
Q1 		$11.7M Buy
296,783
+645
+0.2% +$25.6K 0.66% 60
2015
Q4 		$16.8M Buy
296,138
+27,000
+10% +$1.37M 0.88% 34
2015
Q3 		$10.7M Sell
269,138
-39,540
-13% -$1.91M 0.7% 53
2015
Q2 		$14.7M Sell
308,678
-38,949
-11% -$1.65M 1.14% 21
2015
Q1 		$13.1M Sell
347,627
-107,230
-24% -$3.84M 1.08% 25
2014
Q4 		$10.2M Buy
454,857
+150,948
+50% +$2.86M 0.88% 43
2014
Q3 		$4.76M Buy
303,909
+44,546
+17% +$666K 0.46% 80
2014
Q2 		$3.85M Buy
259,363
+20,803
+9% +$294K 0.35% 97
2014
Q1 		$3.84M Buy
+238,560
New +$4.08M 0.37% 93

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Emerald Mutual Fund Advisers Trust's NBIX Position: Q3 2017 in Review

Emerald Mutual Fund Advisers Trust sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 82,212 shares — an estimated $3.78M sold.

Emerald Mutual Fund Advisers Trust first reported a position in NBIX in Q1 2014 and held it in 14 quarters. The position peaked at $16.8M in Q4 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • Emerald Mutual Fund Advisers Trust reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • Emerald Mutual Fund Advisers Trust sold 82,212 Neurocrine Biosciences shares in Q3 2017, an estimated $3.78M.
  • Emerald Mutual Fund Advisers Trust first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 14 quarters.
  • Emerald Mutual Fund Advisers Trust's Neurocrine Biosciences position peaked at $16.8M in Q4 2015.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Emerald Mutual Fund Advisers Trust's 13F filing for Q3 2017, filed 30 Oct 2017.